TABLE 3.

Change in inhibitory potencies of NNRTIs and NRTIs against different HIV-1 clades

Clade	Fold change in potency compared with that against adrug-sensitive straina
	3TC	TDF	EFV	NVP	MK-4965
Clade A (n = 4)	0.92 ± 0.2	0.95 ± 0.075	0.73 ± 0.35	0.94 ± 0.71	0.73 ± 0.31
CRF01_AE (n = 3)	1.13 ± 0.13	0.78 ± 0.049	0.83 ± 0.10	0.67 ± 0.13	0.90 ± 0.11
CRF02_AG (n = 5)	1.31 ± 0.32	0.93 ± 0.15	0.71 ± 0.13	0.40 ± 0.09	0.92 ± 0.25
Clade B (n = 5)	1.06 ± 0.16	0.94 ± 0.09	1.16 ± 0.63	1.25 ± 1.04	1.25 ± 0.45
CRF17_BF (n = 2)	1.37 ± 0.1	0.83 ± 0.12	0.86 ± 0.09	0.83 ± 0.51	1.15 ± 0.41
Clade C (n = 5)	1.07 ± 0.2	0.97 ± 0.19	0.88 ± 0.44	0.70 ± 0.47	1.07 ± 0.56
Clade D (n = 3)	0.80 ± 0.04	0.74 ± 0.09	0.51 ± 0.01	0.35 ± 0.04	0.56 ± 0.01
Clade F1 (n = 2)	0.87 ± 0.16	0.96 ± 0.09	0.81 ± 0.43	0.73 ± 0.65	0.72 ± 0.25
Clade G (n = 2)	0.70 ± 0.06	0.96 ± 0.06	0.77 ± 0.23	1.25 ± 0.67	0.58 ± 0.13
Clade H (n = 2)	0.83 ± 0.26	0.67 ± 0.03	0.20 ± 0.02	0.13 ± 0.01	0.22 ± 0.01

^aThe drug-sensitive strain was employed as the control to determine the changes in potency.